Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 23,107 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 23,107 shares of the business’s stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75. Following the sale, the chief financial officer now owns 63,222 shares of the company’s stock, valued at $2,987,239.50. The trade was a 26.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Wednesday, May 28th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $52.98, for a total transaction of $613,561.38.
• On Thursday, May 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $60.22, for a total transaction of $697,407.82.
• On Tuesday, April 15th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.50, for a total transaction of $330,058.50.
• On Wednesday, April 2nd, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.26, for a total transaction of $338,860.06.

Hims & Hers Health Price Performance

NYSE HIMS opened at $41.40 on Thursday. The stock has a market capitalization of $9.27 billion, a P/E ratio of 60.00, a PEG ratio of 1.62 and a beta of 2.09. The firm’s 50-day moving average is $49.27 and its two-hundred day moving average is $39.37. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The business’s revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.05 EPS. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Blume Capital Management Inc. boosted its holdings in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the first quarter worth about $30,000. Smartleaf Asset Management LLC boosted its stake in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares during the period. Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $38,000. Finally, UMB Bank n.a. grew its holdings in shares of Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock valued at $39,000 after purchasing an additional 933 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on HIMS shares. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a report on Monday. Piper Sandler reiterated a “neutral” rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Bank of America upped their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a report on Tuesday, April 29th. Citigroup reaffirmed a “sell” rating and issued a $30.00 target price (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Wall Street Zen raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating in a research report on Sunday, June 15th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $38.00.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.